Ignite Creation Date:
2024-05-06 @ 1:38 AM
Last Modification Date:
2024-10-26 @ 11:07 AM
Study NCT ID:
NCT01866592
Status:
COMPLETED
Last Update Posted:
2018-05-22
First Post:
2013-05-16
Brief Title:
Vascular Inflammation in Psoriasis - Extension Study
Sponsor:
University of Pennsylvania
Organization:
University of Pennsylvania
Study Overview
Official Title:
Vascular Inflammation in Psoriasis - Extension Study
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VIP-E
Brief Summary:
VIP-E is a one-arm open-label 40-52 week extension study to continue or cross over subjects of the VIP study 814278 to active drug adalimumab to determine if there is sustained improvement in vascular inflammation lipid metabolism and inflammatory markers VIP-E extends VIP study procedures for 40-52 weeks including questionnaires physical exams blood and urine samples lab tests one additional FDG-PETCT scan and adalimumab injections following FDA-approved psoriasis treatment regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None